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Recent advances in sequencing technologies led to the identification of a plethora of
different genes and several hundreds of amino acid recoding edited positions. Changes
in editing rates of some of these positions were associated with diseases such as
atherosclerosis, myopathy, epilepsy, major depression disorder, schizophrenia and other
mental disorders as well as cancer and brain tumors. This review article summarizes our
current knowledge on that front and presents glycine receptor C-to-U RNA editing as a
first example of disease-associated increased RNA editing that includes assessment of
disease mechanisms of the corresponding gene product in an animal model.
Keywords: RNA editing, epilepsy, cancer, mental disorders, glycine receptor, glutamate receptor, potassium
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INTRODUCTION
The conversion of genetic information from the DNA to the protein level includes the transcription
of a given gene into RNA and its subsequent translation. Protein expression is tightly regulated
at each step, and depends on the presence and activity of a bulk of proteins, which in most
cases are themselves regulated by further proteins, hormones, metabolites or other modulators.
Thus, any cell may generate nearly infinite expression profiles being able e.g., to differentiate in a
tissue-dependent manner during development or to adapt to changes in environmental conditions.
The variability of a genome is further increased by posttranscriptional modifications that change
the genetic information during expression and lead to alternative variants of a given protein.
Posttranscriptional modifications may occur at each step of gene expression and are carried out
by evolutionarily conserved mechanisms. Commonly known posttranscriptional modifications are
the splicing events in the nucleus, RNA editing and the specific insertion of a selenocysteine instead
of a cysteine during translation. This review article focuses on RNA editing of nuclear transcripts
in higher eukaryotes, its mechanisms, systemic relevance and association with development and
disease.
RNA EDITING—ENZYMES AND MECHANISMS
RNA editing was described for the first time in Trypanosomawhere themRNA of themitochondrial
gene coding for cox-2 was found to differ from its expected sequence in terms of four missing
uridines at the 5′ end in comparison to the respective DNA sequence (Benne et al., 1986).
Subsequently to this intriguing discovery, it became clear that this ‘‘RNA editing’’ event occurs
much more frequently, and that about 60% of the genomic information in mitochondria
of Trypanosoma is edited by insertion or deletion of uridines. Nuclear mRNA of higher
eukaryotes was also found to be edited in a reproducible fashion. However, unlike Trypanosoma,
editing of nuclear mRNA in higher eukaryotes is rather a consequence of amination or
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deamination of purines and pyrimidines than a consequence
of nucleotide insertion or deletion. The prevalent type of RNA
editing in higher eukaryotes results from two types of hydrolytic
enzymatic deamination reactions. As discussed below in more
detail, deamination of cytidine leads to the conversion to uridine
(C-to-U), which is dependent on the APOBEC (‘‘apolipoprotein
B mRNA editing enzyme, catalytic polypeptide-like’’) gene
family and auxiliary proteins. Enzymatic deamination of
adenosine yields inosine (A-to-I) and is dependent on the
ADAR (‘‘adenosine deaminase acting on RNA’’) enzyme gene
family. U-to-C and G-to-A RNA editing may also occur due
to amination of the respective bases (Sharma et al., 1994;
Grohmann et al., 2010; Niavarani et al., 2015; Knie et al.,
2016).
THE ADAR GENE FAMILY
Members of the ADAR family catalyze the deamination of
adenosine to inosine except in protozoa, yeast and plants (Jin
et al., 2009). Inosin is interpreted as guanosine (G) during
mRNA translation. ADAR principle function and sites of
action are shown in Figure 1. ADAR enzymes are highly
conserved among invertebrates and vertebrates. Three different
ADAR genes (ADAR1–3) were identified in the mammalian
genome with ADAR1 being the first one (O’Connell and
Keller, 1994; Kim et al., 1994a). During evolution, the ADAR
family putatively arose from adenosine deaminases acting on
tRNA (ADAT), which are conserved from yeast to man
and also have a bacterial ortholog (TadA). Interestingly, the
evolutionary predecessors of adenosine deaminases (ADAT and
ADAR) are cytidine and not adenosine deaminases acting
on mononucleotides, classifying ADARs, like APOBECs, into
the cytidine deaminase family. This viewpoint is corroborated
by comparison of the X-ray structures of the ADAR and
APOBEC catalytic domains (for mechanisms of APOBEC-
dependent RNA editing see below). The deamination motif
of human ADAR2 bears two α-helices (α2 and α5) and
four ß-strands that form a structure similar to the core of
cytidine deaminase catalytic domains (Macbeth et al., 2005).
Another similarity in the structural implications of APOBEC
and ADAR is Zn2+ complexation at the active site of ADAR
that is mediated by the histidine and glutamate residues of
an HAE motif (aa 394–396 in human ADAR2) and the more
distally located cysteine residues C451 and C516 (human
ADAR2). Unlike APOBEC, members of the ADAR family are
able to catalyze deamination without the aid of additional
auxiliary proteins (Nishikura, 2010). This independent mode
of action is perhaps intrinsic to several RNA binding domains
located in the N-terminal part of the ADAR proteins. Thus,
investigation of deamination mechanisms and the search for
in vivo substrates may be more straightforward than in the
case of the APOBEC enzymes. Catalytic activity has only been
shown for the ubiquitously expressed ADAR1 and ADAR2 (Kim
et al., 1994b; Higuchi et al., 2000) but not for brain specific
ADAR3 which may be a regulatory component of the A-to-
I editing machinery as it binds single and double stranded
RNA and was shown to inhibit in vitro the activities of RNA
editing enzymes of the ADAR gene family (Chen et al., 2000;
Nishikura, 2010). Though most of the A-to-I RNA editing
sites were attributed to non-coding genome regions such as
Alu repeats or L1 LINE (Neeman et al., 2006), an increasing
number of A-to-I RNA editing sites in protein coding regions is
identified using advanced sequencing techniques (Levanon et al.,
2005; Li et al., 2009; see http://www.rnaedit.com). Furthermore,
there are some important indications that ADAR-mediated RNA
editing modulates the efficiency of RNAi pathways including
the generation of microRNAs (miRNAs) and the processing of
small interfering RNAs (siRNAs) (Nishikura, 2006). However,
17 different amino acid recoding events can occur due to A-to-I
changes within codons (Figure 1).
RNA and DNA binding of ADAR1 have been attributed
to Z-DNA binding domains, which might confer target site
specificity of editing of viral RNA templates (Brown et al.,
2000) and, thus, play a virus selective role in the host
response to infection (George and Samuel, 2011). When
ADAR1 or ADAR2 is incubated with double-stranded RNA
(dsRNA; >20 bp), about 50% of the adenosine residues will
be edited in a promiscuous fashion (Bass and Weintraub,
1987; Nishikura et al., 1991). However, dsRNA molecules
with imperfectly matched base pairs lead to a more selective
action of ADAR, indicating that the secondary structure
of the RNA substrate is crucial for site specificity of an
ADAR-mediated editing event (Figure 1). Thus, cellular editing
by ADAR occurs preferentially in double stranded RNA with
mismatches, bulges and internal loops, suggesting that target
site selectivity is based on conformation rather than on a
particular sequence (Bass, 1997). The type of mismatch greatly
influences A-to-I editing efficiency, with A:C being preferred
over A:A, A:G or A:U (Wong et al., 2001). Nonetheless, in
some cases A-to-I RNA editing does not occur although the
target position seems to be in the right context (Lehmann
and Bass, 2000). Actually, epigenetic regulation can contribute
to ADAR-dependent A-to-I RNA editing, as was recently
revealed by investigation of the cellular epitranscriptome
and identification of methyl-6-adenosine RNA modification
(Saletore et al., 2013), which blocks ADAR-dependent RNA
editing (Véliz et al., 2003) and may be a ground-breaking
discovery for personalized medical care (see below for a
discussion of A-to-I RNA editing-dependent mechanisms in
disease). Another possibly promising pharmaceutical approach
may consist in targeting RNA splicing. In fact, ADAR2 activity
can lead to creation of new RNA splice sites in ADAR2-coding
mRNA and lead to alternative ADAR splice variants with altered
RNA editing capacity (Rueter et al., 1999).
ADAR-DEPENDENT RNA EDITING IN
DEVELOPMENT
Already 30 years ago, it was postulated that A-to-I RNA
editing may play an important role in development (Bass
and Weintraub, 1987). Indeed, recently, down-regulation of
α3-GABA(A)R expression was shown to result from A-to-I RNA
editing by ADAR1 or ADAR2 at the I/M site (AUA-to-AUG
coding for isoleucine [I] and methionine [M], respectively,
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FIGURE 1 | Principles of A-to-I RNA editing. The hand-drawing top left provides a schematic illustration of the deamination of adenosine to inosine (A-to-I). In
contrast to APOBEC-dependent C-to-U RNA editing, ADARs do not need auxiliary proteins for deamination but rely on secondary mRNA structure motifs within
introns (bottom-left). A-to-I RNA editing can lead to indicated (right-hand) amino acid recoding events. Selected edited products and their possible involvement in
disease are discussed in this review article.
Figure 1), which impairs GABA(A)R α3 surface expression,
suggesting that by trafficking control of α3-containing receptors
RNA editing may facilitate the switch of subunit compositions
during development and affect the subcellular distribution of
α subunits in the adult brain (Ohlson et al., 2007; Daniel
et al., 2011). Switching subunit compositions may accelerate
GABAergic synaptic response kinetics and enhance spike-timing
precision at more mature developmental states, as GABA(A)R
α3 expression is developmentally downregulated andGABA(A)R
α1-coding mRNA cannot be edited at the I/M position (because
AUU encodes isoleucine in mouse, rat and human; Lavoie et al.,
1997; Jüttner et al., 2001).
Due to the advances in sequencing techniques a recent
study could survey changes in the global landscape of A-to-I
RNA editing in human brain tissues and revealed many
more gene products that undergo developmental and disease-
specific changes in gene expression. Thereby a spatiotemporal
atlas of RNA editing was created that revealed a dynamic
profile of RNA editing (Hwang et al., 2016). This pioneering
study revealed three patterns of uniquely regulated RNA
editing sites during cortical development from fetal to old
age comprising stably high, stably low, and increasing editing
at given sites. The increasing pattern of A-to-I RNA editing
included sites in vesicle or organelle membrane-related genes
and glutamate signaling pathways. In two selected disorders,
namely spinal cord injury and glioblastoma, perturbed A-to-I
RNA editing could be demonstrated, as discussed below in more
detail.
ADAR-DEPENDENT RNA EDITING IN
DISEASE
The pioneer studies by Peter H. Seeburg revealed a critical
position that, amongst others, determines the calcium
permeability of the AMPA-type ionotropic glutamate
receptor channel and is situated in the hairpin loop between
transmembrane domains 1 and 3 (Seeburg et al., 2001). In this
case, A-to-I RNA editing at the Q/R site (CAG-to-CGG) of
the AMPA receptor subunit GluA2 occurs at a rate of virtually
100% (Figure 1). Genetically engineered mice that carry an
editing resistant Q/R site in Gria2—with 70% GluA2 mRNA
expression from wild-type and 75% editing vs. 100% in wild-
type—develop severe epilepsy with generalized seizures and
premature postnatal lethality (Brusa et al., 1995). A conditional
mouse model with deficient GluA2 Q/R editing only in forebrain
had its seizure origin in the hippocampus (Krestel et al.,
2004). To test the hypothesis whether editing deficiency at the
GluA2 Q/R site contributes to human mesial temporal lobe
epilepsy (TLE), hippocampi from patients who had undergone
surgery for pharmacotherapy-resistant epilepsy were analyzed.
It turned out that: (i) the GluA2 Q/R site editing belongs to
the stably high editing pattern with 100% editing in all patients
analyzed aged from 5 years to 57 years at the time of surgery;
(ii) epilepsy could not perturb this stably high pattern; and
(iii) epilepsy in mice due to deficient GluA2 Q/R site editing
probably was an artifact of genetic engineering (Krestel et al.,
2013).
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In patients with amyotrophic lateral sclerosis, decreased RNA
editing at the Q/R site was found to occur in motor neurons
(Kwak and Kawahara, 2005; Figure 2). In fact, ADAR2 gene
targeting in motor neurons provokes a decline in motor function
and the phenotype can be reverted if themice express RNA edited
GluA2 (Higuchi et al., 2000; Hideyama et al., 2010). Reduced
A-to-I RNA editing at the Q/R site of GluA2 was furthermore
shown to be associated with glioblastoma (Maas et al., 2001;
Figure 2). However, in spinal cord injury and glioblastoma,
the developmentally increasing pattern of A-to-I RNA editing
of many gene transcripts seems to be disrupted (Hwang
et al., 2016), raising the question about underlying mechanisms
of these diseases (Fu et al., 2016), including investigation
of ‘‘master’’ genes that regulate function of down-stream
genes and thus govern signaling cascades involved in disease.
Regarding GluA2 under-editing, which was more pronounced
in glioblastoma compared to neighboring non-tumor tissue
(Hwang et al., 2016), and taking into account that brain
tumor cells can release glutamate by transferrin-mediated iron
accumulation (Chirasani et al., 2009), reduced RNA editing and
increased calcium signaling through GluA2 may contribute to
aggressiveness of tumor growth and expansion. Regarding spinal
cord injury in a mouse model (Chen et al., 2013), decreased RNA
editing of GluA2 in the epicenter of the injured site actually
points to a disease-promoting mechanism, as cellular calcium
overload should promote neurodegeneration.
Moreover, changes in ADAR-mediated A-to-I RNA editing
were associated with several other types of cancer, including
breast cancer, neuroblastoma and hepatocellular carcinoma; for a
review see Fu et al. (2016), suggesting that some common master
gene products may be involved in the pathogenesis of these
diverse diseases. Finally, in human postmortem brains of patients
with schizophrenia and bipolar disorder ADAR2 expression
tended to be decreased, and decreased ADAR2 expression was
significantly correlated with decreased editing of the R/G sites of
AMPA receptors (Kubota-Sakashita et al., 2014; Figures 1, 2). All
these examples point to a crucial role of AMPA-type glutamate
receptor RNA editing in many disease conditions, but the
underlying mechanisms still remain obscured and need to be
addressed. Although RNA splicing of ADAR2 may provide
correlative mechanistic insights into the interrelation between
enzyme function and RNA editing (Fu et al., 2016), identification
of a general downstream mechanism of disease manifestation,
e.g., changes in calcium signaling, would eventually reveal
promising strategies to tackle these diseases early in their
pathomechanisms.
Serotonergic neurotransmission was shown to be influenced
by RNA editing of serotonin receptors (5-HT2C-R; Gurevich
et al., 2002a; Figures 1, 2). A-to-I RNA editing of 5-HT2C-R
at up to five positions decreases the apparent receptor affinity
to serotonin, with codon 158 (AAU-to-AGU [C site] or –GAU
[E site] or –GGU [C and E sites]) in the intracellular loop between
transmembrane domains 3 and 4 producing the strongest effects
(up to a 20-fold decrease; Fitzgerald et al., 1999). Editing of
5-HT2C-R thus seems to be a versatile tool for neurons to
dynamically adjust receptor response properties to alterations
in serotonin levels. This is an economic way of regulation as
FIGURE 2 | Pathophysiological implications of altered
ADAR-dependent RNA editing in disease. Both up- and down-regulation
of A-to-I RNA editing (indicated by orange and blue colors, respectively) were
associated with several, different diseases. Note that up-regulation of
GABAAR α3 RNA editing makes an exception as it plays a role in development
(indicated by gray text color).
it bypasses the need for supplementary genes (or exons that
could be alternatively spliced) and associated regulation of gene
expression. However, the mechanism may also fail as a complex
pattern of altered RNA editing in depressed suicide victims was
suggested to exacerbate the effects of low serotonin (Gurevich
et al., 2002b; Figure 2). Furthermore, G-to-A RNA editing occurs
in transcripts coding for tryptophan hydroxylase 2 (TPH2a)
that controls brain serotonin synthesis (Grohmann et al., 2010).
In this case, G-to-A editing leads to amino acid substitution
R441H that decreases TPH2a enzyme activity and, thus, may
also contribute to major depression disorder (Grohmann et al.,
2010; Figure 2). In fact, coincident changes in RNA editing of
both 5-HT2C-R and TPH2 may result in a cumulative decrease
in 5-HT signaling, constituting a worst-case scenario for the
patients.
Potassium channels also undergo A-to-I RNA editing which
substitutes valine for isoleucine at position 400 (I400V) within
the transmembrane domain 6 of human Kv1.1 (Bhalla et al.,
2004). The resulting accelerated recovery from inactivation and
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increase in K+ outward current upon membrane depolarization
(Bhalla et al., 2004) can stabilize repolarization through
Kv1.1 potassium channels and thus control neuronal excitability.
The Kv1.1 I/V site belongs to the ‘‘increasing pattern’’ observed
in human brain development (Hwang et al., 2016), as mentioned
above. On the other side, a decrease of RNA editing may
translate into destabilized repolarization and may contribute
to the maintenance of neuronal hyperexcitability. Remarkable
in this context is the observation that the RNA editing rate
decreases with epilepsy duration in the removed hippocampus
of patients who underwent surgery for intractable mesial TLE
with hippocampal sclerosis but not with other clinical parameters
(Figure 2). A specific association of the decrease with either the
epileptic process itself or its antiepileptic medication history was
suggested (Krestel et al., 2013).
THE APOBEC GENE FAMILY
The successful cloning of APOBEC-1, the first identified
member of the APOBEC gene family of cytidine deaminases
(Navaratnam et al., 1993; Teng et al., 1993), signified an
important hallmark in research of the molecular components
of the mammalian C-to-U editosome. APOBEC is a family
of evolutionarily conserved proteins. As of today, 10
additional cytidine deaminases homologous to APOBEC-1
and thus contributing to the APOBEC gene family were
identified (APOBEC-1, -2, -3A, -3B, -3C, -3D, 3E, -3F, -3G,
-3H, -4; activation-induced cytidine deaminase (AID);
Bransteitter et al., 2009). While members of the APOBEC
enzyme family are responsible for editing of pre-mRNA,
single stranded DNA (ssDNA) and genomic DNA, AID
seems to mostly edit ssDNA and contribute to the adaptive
immune response by introducing dC-to-dU mutations into
the VDJ region of the immunoglobulin gene (Conticello,
2008). APOBEC-1 is the best characterized member of the
APOBEC gene family. Thanks to the pioneer work of Harold
C. Smith, the role of APOBEC-1 and auxiliary proteins in
pre-mRNA editing of apolipoprotein B (ApoB) was elucidated
in great detail (Backus and Smith, 1992; Schock et al., 1996;
Dance et al., 2002; Smith, 2007). The role of APOBEC-2
was discovered more recently. APOBEC-2 was shown to be
involved in C-to-U RNA editing of eukaryotic translation
initiation factor 4 gamma 2 as well as phosphatase and
tensin homolog (PTEN) genes and to be associated with
tumorigenesis (Okuyama et al., 2012). In addition, APOBEC-2
plays a crucial role in muscle development (Sato et al., 2010)
and in the TGFß-mediated manifestation of internal organ
left-right asymmetry during development (Vonica et al., 2011).
APOBEC-3A-H can inhibit the propagation of HIV and human
papillomavirus (HPV) by editing the viral double-stranded
cDNA intermediates that serve as template for the expression
of viral proteins (Conticello, 2008; McDougall et al., 2011).
APOBEC-3B may preferentially edit genomic DNA and is
implicated in cancer as its expression correlates with increased
DNA damage and thus represents an enzymatic source of
mutation in breast cancer (Burns et al., 2013). APOBEC-3G
edits ssDNA under certain conditions (McDougall et al.,
2011). By deaminating C to U and thus inserting mutations,
APOBEC-3G might protect the mammalian genome against
the spread of retroviruses. Supportive evidence comes from
the upregulated expression of APOBEC-3G in inflammatory
skin disorders such as Lichen planus. This disease is believed to
be associated with activation of quiescent human endogenous
retroviruses, and upregulation of APOBEC-3G is perceived
as an endogenous defense mechanism (Nogueira et al., 2015).
APOBEC-4 was found by in silico methods (Rogozin et al.,
2005) and appears to influence HIV-1 expression (Marino et al.,
2016).
A common feature of all members of the APOBEC family
is an N-terminal catalytic domain comprising the sequence
HXEX27/28PCXXC (Jarmuz et al., 2002) that coordinates a
Zn2+ ion within the active center of the enzymes. The tertiary
structure of APOBEC catalytic domains, derived from X-ray
and NMR studies on APOBEC-2 (Prochnow et al., 2007)
and APOBEC-3G (CD2, a C-terminal additional catalytic
domain only present in some APOBEC isoforms; Chen et al.,
2008; Holden et al., 2008), is composed of a five ß-strands
containing ß-sheet that is surrounded by six α-helices. In
the case of full-length APOBEC-2, homo-tetramerization
has been shown to prevent the active site of the catalytic
domains to be accessible to nucleic acids (Prochnow et al.,
2007), counteracting the catalytic activity of the enzyme.
This self-inhibitory action of APOBEC-2 might explain
why demonstration of in vivo deamination activity of this
isoform is rather challenging. However, the C-to-U RNA
editing mediated by APOBEC-1 depends on many auxiliary
proteins (Blanc and Davidson, 2010; Table 1 and Figure 3).
Although APOBEC-1 itself can accommodate RNA substrates
involving zinc-finger domains and, additionally, two critical
phenylalanines (Anant et al., 1995; Navaratnam et al., 1995),
APOBEC-1 complementation factor (ACF) is essential for
editing activity (Schock et al., 1996; Mehta et al., 2000).
ACF contains RNA recognition motifs (RRM) that direct
APOBEC-1 to the target sites (Lellek et al., 2000; Mehta
et al., 2000; Henderson et al., 2001). These RRM domains
bind to the mooring sequence UGAUCAGUAUA located
downstream of the edited position and thus confer target
specificity (Smith, 2007), while the C-terminal auxiliary
domain of ACF is required for interaction with APOBEC-1
(Mehta and Driscoll, 2002). Furthermore, the RNA-binding
protein CUGBP2 is part of the APOBEC-1 holoenzyme and
specifically targets AU-rich elements immediately upstream
of the edited position (Anant et al., 2001). Many other
factors have also been shown to modulate ApoB RNA
editing, although in these cases the mechanisms are less
well understood (Table 1). APOBEC-1 knockout mice do
not edit ApoB mRNA (Hirano et al., 1996; Nakamuta et al.,
1996), even though these mice express other members of the
APOBEC gene family, indicating the intriguing specificity
of this editing process. APOBEC-1 and ACF are present
in both cytoplasm and nucleus but within the progress of
protein expression, ApoB mRNA editing appears to be not
cytosolic but intra-nuclear and post-transcriptional (Lau et al.,
1991; Blanc and Davidson, 2010). A detailed review of the
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TABLE 1 | APOBEC-1 auxiliary proteins.
Name Function Effect on C-to-U RNA editing Reference
ACF RNA binding (mooring sequence UGAUCAGU-AUA) and interaction with APOBEC-1 ↑ Mehta and Driscoll (2002)
Sowden et al. (2004)
CUGBP2 RNA binding (AU-rich elements) and ACF interaction ↑ Anant et al. (2001)
GRY-RBP RNA binding and interaction with ACF and APOBEC-1 ↓ Blanc et al. (2001)
hnRNP C1 RNA binding and interaction with APOBEC-1 ↓ Greeve et al. (1998)
ABBP-2 Interaction with APOBEC-1 ↑ Lau et al. (2001)
BAG-4 Interaction with APOBEC-1 and re-routing to the perinucleolar compartment ↓ Lau and Chan (2003)
AUX240 Editosome assembly ↑ Schock et al. (1996)
current knowledge about ApoB mRNA editing by APOBEC-1
was recently published by Harold C. Smith (Prohaska et al.,
2014).
C-to-U RNA editing can lead to 13 different amino acid
recoding events, with two of them leading to a STOP codon, as
shown in Figure 3. In the following section, examples of amino
acid recoding C-to-U RNA editing associated with disease will be
presented.
APOBEC-DEPENDENT RNA EDITING IN
DISEASE
The mRNA coding for ApoB is C-to-U RNA edited (Boström
et al., 1990). By regulating low and high density lipoprotein
metabolism, RNA editing and the resulting biosynthesis of
truncated ApoB48 protein is a critical regulator of plasma
cholesterol content (Nakamuta et al., 1996), and dysregulation
of APOBEC-1-dependent ApoB48 expression results in
hypercholesterolemia and atherosclerosis (Fu et al., 2004;
Figure 4).
As mentioned above, G-to-A editing leads to amino acid
substitution R441H that decreases TPH2a enzyme activity
(Grohmann et al., 2010). However, the alternatively spliced
TPH2b enzyme can be C-to-U RNA-edited within the splice
insert exon 3b, leading to c.385C>T and a truncated protein
variant due to Q129X substitution (Grohmann et al., 2010).
Editing at this position of TPH2b transcripts of suicides
and patients with schizophrenia decreased substantially
by 50% and 30%, respectively (Grohmann et al., 2010;
Figure 4).
Changes in C-to-U RNA editing were also associated with
several other diseases. In particular, APOBEC-2 deficient mice
showed a markedly increased ratio of slow to fast fibers in
soleus muscle and exhibited a reduction in body mass from birth
onwards, with elderly mutant animals revealing clear histological
evidence of a mild myopathy (Sato et al., 2010; Figure 4).
Increased expression of APOBEC-2 in the liver resulted in
FIGURE 3 | Principles of C-to-U RNA editing. The hand-drawing top left provides a schematic illustration of the deamination of cytidine to uridine (C-to-U). In
contrast to ADAR-dependent A-to-I RNA editing, APOBEC needs auxiliary proteins for deamination as detailed in Table 1 and exemplified in the bottom-left panel.
Thus, the mature mRNA can be RNA-edited. C-to-U RNA editing can lead to indicated (right-hand) amino acid recoding events. Some selected gene products
associated with disease (in brackets) and their possible involvement in disease are discussed in this review article.
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significantly high frequencies of nucleotide alterations in the
transcripts of eukaryotic translation initiation factor 4 gamma 2
as well as PTEN and was accompanied by hepatocellular
carcinoma in 10% of 72 weeks old animals as well as lung
tumors in 35% of transgenic mice analyzed (Okuyama et al.,
2012; Figure 4).
APOBEC-3B seems to be an enzymatic source of mutation
in breast cancer (Burns et al., 2013). In particular, the DNA
cytosine deaminase activity of APOBEC-3B was shown to be
up-regulated in primary breast tumors and breast cancer cell lines
(Figure 4), suggesting that APOBEC3B-catalyzed deamination
provides a chronic source of DNA damage in breast cancers that
could select TP53 inactivation and explain how some tumors
evolve rapidly and manifest heterogeneity. (Burns et al., 2013).
Surprisingly, in the case of Wilms Tumor 1, APOBEC-3A was
associated with a novel form of G-to-A editing, perhaps opening
a way to further investigations into the mechanisms of other
potential mRNA changes and helping us to redefine the RNA
editing paradigm in both health and disease (Niavarani et al.,
2015).
Although APOBEC-4 did not show any deamination activity,
it was shown to enhance the replication of HIV-1, suggesting a
natural role in modulating host promoters or endogenous long
terminal repeat (LTR) promoters rather than being a cytosine
deaminase (Marino et al., 2016).
Again, the description of global changes in C-to-U RNA
editing due to changes in APOBEC-2, APOBEC-3 or APOBEC-4
function is not sufficient and can just be a starting point
for the investigation of the critical targets that govern disease
progression in the various kinds of diseases described here.
Like GABA type A receptors the neurotransmitter receptors
for glycine (GlyRs) belong to the ligand-gated ion channel
gene superfamily and are glycine-gated chloride channels
which were involved in TLE, inflammatory pain sensitization,
autism spectrum disorder and glioblastoma (Harvey et al.,
2004; Eichler et al., 2008; Förstera et al., 2014; Pilorge et al.,
2016). GlyRs are C-to-U RNA edited although the mooring
sequence recognized by ACF is not very well conserved (Meier
et al., 2005). In this case, C-to-U RNA editing leads to a
gain-of-function as the resulting amino acid substitutions
P185L (in GlyR α1 and α3 subunits) and P192L (in GlyR α2)
increase apparent agonist affinities of the neurotransmitter
receptors (see Eichler et al., 2008; Legendre et al., 2009; and
Figures 5A,B). Actually, C-to-U RNA editing of GlyRs was
shown to be increased in the hippocampus of patients with
pharmacoresistant TLE (Eichler et al., 2008; Figures 4, 5),
suggesting that it plays a critical role in this disease. To
test this hypothesis, a corresponding animal model was
generated and allowed investigation of neuron type-specific
mechanisms of RNA-edited GlyR action (Winkelmann et al.,
2014). In sharp contrast to the still prevailing dogma that
GlyRs are exclusively located at the postsynaptic site of
synaptic signaling (Tyagarajan and Fritschy, 2014), we found
that RNA-edited GlyRs are expressed at the presynaptic
terminals of hippocampal neurons (Winkelmann et al.,
2014). This is due to RNA splicing of the GlyR α3 subunit
(Nikolic et al., 1998; Eichler et al., 2009) and substantiated
FIGURE 4 | Pathophysiological implications of altered
APOBEC-dependent RNA editing in disease. Both up- and
down-regulation of C-to-U RNA editing (indicated by orange and blue colors,
respectively) were associated with several, different diseases. However,
compared to diseases that have been associated with altered A-to-I RNA
editing, this list is rather short. In particular, in half of the cases, the question
marks indicate global changes in C-to-U RNA editing due to changes in
enzyme expression without identification of specific gene products that were
associated with up- or down-regulation of the APOBEC enzymes in animal
models or tissue samples of patients. The red framed example is discussed in
more detail in this review article.
for other GlyR subunits due to the absence of GlyR β protein
in the hippocampus (Weltzien et al., 2012). Actually, other
researchers also highlight the importance of presynaptic
GlyRs (for examples see Lee et al., 2009; Kubota et al., 2010;
Waseem and Fedorovich, 2010). However, even if GlyRs are
expressed at both presynaptic and postsynaptic sites, a small
number of presynaptic RNA-edited gain-of-function GlyRs
even a single cluster of the non-RNA-edited GlyR α3L splice
variant, which contains up to 200 receptor channels (Notelaers
et al., 2012), will have a greater impact on the presynaptic
membrane potential due to the much smaller volume and
hence electrical capacity of this compartment compared to the
somatodendritic compartment (Meier et al., 2014). Notably
in this context, application of a low glycine concentration
(10 µM) to hippocampal slice preparations enhanced the
occurrence of epileptiform activity whereas a high glycine
concentration (100 µM) attenuated recurrent epileptiform
discharge (Chen et al., 2014). These divergent effects can
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FIGURE 5 | Example of a RNA editing-dependent bedside-to-bench approach. (A) GlyR C-to-U RNA editing leads to amino acid recoding in the ligand
binding domain (P185L or P192L, indicated by the orange filled red framed arrow); modified from Legendre et al. (2009). (B) The amino acid recoding increases
apparent GlyR affinity to glycine irrespectively of the subunit composition as discussed in the main text. Panel (B) is reproduced from Legendre et al. (2009) and
shown here again for the purpose of clarity. (C) Increased RNA editing of GlyR-coding mRNA in patients with temporal lobe epilepsy (TLE) as documented in 2008 by
Eichler and colleagues. In a corresponding mouse model of TLE RNA-edited GlyRs elicited different neuropsychiatric symptoms depending on the neuron type that
expressed these receptor variants, compared to control animals without expression of RNA-edited GlyR and indicated by red framed yellow arrows and the black
framed gray arrow, respectively, placed between (B,C). (D) It is the presynaptic function of RNA-edited GlyRs that is responsible for increased neuronal impact on
network function and the neuron type-specific neuropsychiatric symptoms described in the main text and shown in panel (C).
be explained by preponderant functional impact of low
glycine on presynaptic GlyRs expressed at glutamatergic
terminals, resulting in facilitated glutamate release, and
massive recruitment of somatodendritic GlyR activation by
100 µM glycine, resulting in tonic inhibition, respectively.
Based on current evidence we believe that the presynaptic
compartment is particularly vulnerable to maladaptive
changes in neurotransmitter receptor signaling in disease
(for a review see Meier et al., 2014). In the context of the
rather low neuronal ambient glycine concentration in the
hippocampus, presynaptic RNA-edited GlyRs were indeed
shown to facilitate neurotransmitter release and contribute to
gain-of-function of the affected neuron types, which elicited
neuropsychiatric symptoms like cognitive dysfunction or
persistence of contextual fear memory in our animal model. The
different symptoms depended on the neuron type that expressed
the RNA-edited GlyR variant, namely glutamatergic principle
neurons (Camk2a-Cre) and parvalbumin-positive neurons
(Pvalb-Cre), respectively (Winkelmann et al., 2014; Çalıs¸kan
et al., 2016; Figures 5C,D). As these symptoms of the genetically
targeted mice are reminiscent of the disease symptomatology
of TLE patients, we are currently investigating whether novel
molecular and chemical tools (antagonists of RNA-edited
GlyRs) are able to identify the neuron types with increased GlyR
RNA editing in the hippocampus of patients with TLE and to
counterbalance GlyR-dependent changes in neural network
excitability. However, and most importantly, these studies
demonstrate that it is not sufficient to study changes in RNA
editing using bulk material because the same RNA-edited gene
product (i.e., GlyR) can elicit completely different symptoms,
depending on the neuron type that expresses the pathogenic
RNA-edited protein variant.
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CONCLUSION AND PERSPECTIVE
RNA editing is an evolutionarily conserved process that has
several advantages over gene mutation. Like alternative RNA
splicing, the extent of RNA editing may be regulated, resulting
in increased genomic variance. Furthermore, mRNA variability
can be regulated whereas gene mutations are permanent. It
seems as if there is reasonable evidence supporting altered RNA
processing in a wide range of disease, including paroxysmal
and neoplastic disorders of the brain, neuromuscular disease, as
well as lung and liver disease and breast cancer. The examples
discussed in this review article actually point to a critical role
of deviation from normal RNA processing/editing in disease
ontology and/or the epitranscriptomics of disease. However,
there are several hundreds more amino acid recoding RNA
editing events in many different gene products including gene
regulatory transcripts (see http://www.rnaedit.com) that require
investigation at the functional level; some of which may turn
out to be the master regulatory targets of the editing machinery
and disease-promoting cellular programs. Thus, we are just
at begining of a new era of research that will ultimately
need to identify functional changes of gene products due to
amino acid recoding RNA editing and identify molecular key
players that are masters and hence could signal upstream of,
and regulate RNA processing machines. Furthermore, using
animal models, in depth characterization of the functional
consequences at both molecular and cellular levels are required
to identify mechanisms that are responsible for the diverse
phenotypes and disease symptomatology. The fact that there is
an increasing number of patients with unknown cause of disease
further underscores the need for characterization of causes and
effects of epitranscriptional pathophysiological deviation from
normal RNA processing, hopefully providing a future good
starting point for the development of novel, genuine, therapeutic
concepts.
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